Literature DB >> 18762337

Favorable outcome with chemo-immunotherapy in Burkitt lymphoma and leukemia.

Laimonas Griskevicius, Rokas Stulpinas, Indre Vengalyte, Sonata Saulyte-Trakymiene, Ugnius Mickys, Darius Pranys, Juozas Kurtinaitis, Mindaugas Jurgutis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18762337     DOI： 10.1016/j.leukres.2008.07.024

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  2 in total

1.  Disruption of HLA class II antigen presentation in Burkitt lymphoma: implication of a 47,000 MW acid labile protein in CD4+ T-cell recognition.

Authors:  Jason M God; Dan Zhao; Christine A Cameron; Shereen Amria; Jennifer R Bethard; Azizul Haque
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

Review 2.  Treatment of adolescents with aggressive B-cell malignancies: the pediatric experience.

Authors:  Jonas Lange; Birgit Burkhardt
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.